RGNX
REGENXBIO Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow -3.3% ·
net new positions -7.1%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 93.42K | $730,149 | n/a | n/a |
| Q2 2026 | 76 | 0 | 31.71M | $379.43M | +8 | −8 |
| Q1 2026 | 78 | -5 | 30.64M | $255.01M | +3 | −8 |
| Q4 2025 | 83 | +2 | 30.25M | $435.60M | +2 | n/a |
| Q3 2025 | 14 | -1 | 26.58M | $256.50M | n/a | −1 |
| Q2 2025 | 12 | 0 | 15.85M | $130.14M | n/a | n/a |
| Q1 2025 | 9 | -3 | 5.03M | $35.96M | +1 | −4 |
| Q4 2024 | 12 | +4 | 6.91M | $53.43M | +4 | n/a |
| Q3 2024 | 7 | -3 | 1.79M | $18.80M | n/a | −3 |
| Q2 2024 | 10 | n/a | 2.06M | $24.11M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | JPMorgan Chase ✦ | 8.07M | n/a | $77.92M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 2 | BlackRock ✦ (passive) | 6.37M | -5.7% | $61.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×11 |
| 3 | The Vanguard Group ✦ (passive) | 3.34M | -2.4% | $32.21M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | State Street Global Advisors ✦ (passive) | 1.98M | +7.7% | $19.15M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Goldman Sachs Group ✦ | 1.85M | n/a | $17.87M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Morgan Stanley ✦ | 1.70M | n/a | $16.45M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 7 | AQR Capital Management ✦ | 1.29M | +38.6% | $12.45M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 8 | Geode Capital Management ✦ (passive) | 1.13M | -0.3% | $10.86M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 309.49K | -57.9% | $2.99M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 195.19K | +13.8% | $1.88M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 11 | Two Sigma Investments ✦ | 154.29K | -25.8% | $1.49M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | Millennium Management ✦ | 86.66K | -22.6% | $836,259 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 55.52K | -81.0% | $535,797 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 38.99K | +39.4% | $377,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $1.83M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 177 holders, 39.19M shares, $343.14M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 53.41K sh @ 9.36 · $499,676
Director · 49.20K sh @ 9.14 · $449,706
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology